Here's Why TG Therapeutics Stock Is Getting Hammered Today

·2 min read
Here's Why TG Therapeutics Stock Is Getting Hammered Today

A second-quarter earnings report reminded investors how difficult it is for independent companies to launch new cancer drugs.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting